本团队建立了被国际公认并称之为“北京方案”的单倍体相合造血干细胞移植体系，基本解决了供者来源问题，使人人能移植。黄晓军初步阐明了单倍体移植免疫耐受机制，粒细胞集落刺激因子及抗胸腺细胞球蛋白是跨越免疫屏障的关键，建立并完善了造血干细胞移植后复发防治的独特综合体系。张晓辉从巨核细胞成熟障碍及T细胞介导的免疫损伤视角阐明移植后植入不良的免疫学机制，发现多种植入不良相关分子，为干预性临床研究提供了可评估标记。常英军阐明了免疫重建的规律，并基于分子标记物实现了移植物抗宿主病的预警及分层防治模式。葛青建立了多种研究胸腺输出功能的体内外模型，为阐明移植后T细胞胸腺内外发育及功能形成奠定了基础。蒋争凡和赵翔宇发现了连接天然免疫与适应性免疫信号传导通路的重要分子，阐明了移植后免疫重建与病毒感染的关系，为移植后抗病毒干预提供了新靶点和策略。上述工作均围绕移植展开，为进一步阐明移植应用机制、提高疗效奠定了基础。

The system of haploidentical hematopoietic stem cell transplantation (HSCT) which was established by our team has been internationally recognized as “Peking Protocol”. It made transplant donors available for each person and generally solved the problem of “Donor Shortage”. Prof. Xiaojun Huang elucidated its cellular mechanisms of immune tolerance: granulocyte colony-stimulating factor and antithymocyte globulin play the key role in overcoming the immune barrier. In addition, he established and enriched a new system to prevent and treat leukemia relapse after HSCT. Prof. Xiaohui Zhang clarified the immune pathogenesis of poor platelet engraftment post-transplant from two aspects: megakaryocyte immaturity and the T cell-mediated immunological injury. He found a number of poor engraftment-associated molecules and provided the valuable markers for interventional clinical trials. Prof. Yingjun Chang clarified the patterns of immune reconstitution and established a risk-stratification directed prophylaxis strategy for graft-versus-host disease (GVHD). Prof. Zhengfan Jiang and Dr. Xiangyu Zhao found the important molecule that connects innate immunity with adaptive immunity, and clarified the relationship between immune reconstitution and virus infection post-transplant, which provided the new targets and strategies for anti-virus intervention. All these studies are closely linked with post-transplant issues and lay a good foundation to elucidate the common mechanisms behind its clinic application, which might develop to innovative strategies to further improve therapeutic effects.